默沙东婴儿单剂量RSV抗体药获FDA批准上市

CPHI制药在线
12 Jun

关注并星标CPHI制药在线当地时间6月9日,默沙东宣布其Clesrovimab(商品名ENFLONSIA)已获FDA批准上市,这款长效单克隆抗体疗法用于预防新生儿及进入首个RSV季节的婴儿发生RSV相关的下呼吸道疾病,为婴幼儿提供覆盖整个典型RSV流行季节的保护,这是首个也是唯一一个针对婴儿的单剂量RSV单抗。图源:默沙东官网Enflonsia采用固定剂量设计,无论婴儿体重如何,均统一使用105...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10